Press Releases NKGen Biotech, Inc.

Equities

NKGN

US65488A1016

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-07-04 pm EDT			5-day change	1st Jan Change
1.34 ^USD	+2.29%		+5.51%	-51.27%

Jul. 01	NKGen Biotech, Inc.(NasdaqGM:NKGN) added to Russell Microcap Growth Index	CI
Jul. 01	NKGen Biotech, Inc.(NasdaqGM:NKGN) added to Russell 3000E Index	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024	Jun. 12	GL
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024	Jun. 12	AQ
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024	Jun. 03	AQ
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL	May. 24	AQ
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	May. 23	AQ
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease	May. 20	AQ
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition	May. 16	AQ
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease	Apr. 29	AQ
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	Apr. 25	AQ
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology Annual Meeting	Apr. 25	AQ
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Apr. 24	AQ
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's and Parkinson's Drug Development Summit	Apr. 19	AQ
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	Apr. 18	AQ
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs	Apr. 11	AQ
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's disease at the Tau2024 Global Conference	Mar. 26	AQ
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference	Mar. 25	AQ
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference	Mar. 04	AQ
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies	Feb. 07	AQ
NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial	Dec. 29	AQ
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease	Dec. 28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NKGen Biotech, Inc.

Equities

NKGN

US65488A1016

Press Releases

Filters